The Advisory Board will guide the development of unique topical medications based on the company's water-free hyliQ technology platform.

Dermaliq Therapeutics, Inc. has formed a Scientific and Medical Advisory Board.

New members include Gordon Dow, Xavier Yon, Michael Kuligowski, MD, PhD, and R. Todd Plott, MD. The Advisory Board is composed of key clinical investigators and industry veterans in the field who support and guide the development of unique topical medications based on our water-free hyliQ technology platform. Mr. Dow has been named Chairman of the Advisory board.

“We are pleased to welcome four highly respected members to our Scientific and Medical Advisory Board as we now advance three programs into the clinic: DLQ01 (Androgenetic Alopecia), DLQ02 (Psoriasis) and DLQ03 (Bacterial Skin and Soft Tissue Infections),” says Frank Loescher, PhD, CEO of Dermaliq in a news release.  “The vast clinical and research expertise in dermatology of this group is invaluable for shaping Dermaliq’s current and future product development strategy. The board and the entire team look forward to working closely with them.”

Gordon Dow, PharmD (Chairman) is former CEO, Founder & CTO of Dow Pharmaceutical Sciences Inc. Dow was acquired by Valeant, now Bausch Health, for US$ 400 million in 2008. Dr. Dow is a recognized expert in topical product formulations and a leading innovator for a number of approved and successful dermatology products. “Dermaliq’s hyliQ platform is a step forward in topical formulations and has the potential of being the first real game-changer in dermal delivery since decades,” says Dow.

Michael Kuligowski, MD, PhD, MBA, is Vice President, Global Product Development, Dermatology at Thermo Fisher. His pharmaceutical experience spans 25+ years in companies of various sizes In Europe and in North America. Dr. Kuligowski played a key role in the development and approval of the first topical JAK-inhibitor at Incyte where he served as Executive Medical Director, Inflammation & Autoimmunity.  “Better and more effective topical products are needed to serve the needs of patients and practicing physicians. Innovation in the topical space is needed to develop formulations which can provide safe, enhanced drug delivery, especially for substances which are difficult to solubilize and maintain stability. Dermaliq’s novel drug delivery has the promise to address these needs,” says Dr. Kuligowski.

R. Todd Plott, MD, is a board-certified dermatologist in the Dallas/Fort Worth area and Chief Medical Officer of Epiphany Dermatology. Before entering private practice, Dr Plott spent 16 years in the pharmaceutical industry developing several dermatology drugs widely prescribed by dermatologists, his most notable invention is Solodyn. “Treatment of dermatology diseases remains unsatisfactory for many patients. Dermaliq’s lead developments in psoriasis and skin infections offer an intriguing proposition if confirmed in the upcoming clinical trials” says Dr. Plott.

Xavier Yon, is former CEO of Galderma and has ab extensive background in dermatology. Previous roles include executive positions with Pfizer, Solvay, Alcon and most notably as Chief Executive Officer of Galderma for 17 years. During his time at Galderma Mr. Yon built the company from its initial spin out from Alcon to be a world leader in ethical dermatology. Mr. Yon holds a degree in Physics, Chemistry and Biology from Sorbonne University, Paris. “Dermaliq offers the opportunity to establish a highly attractive product portfolio based on its hyliQ platform, with increased patient compliance and greater patient satisfaction due to the unique platform-related cosmetic properties”, says  Mr. Yon.

About Dermaliq

Dermaliq Therapeutics, Inc. is a private company founded in 2021 through a spin off from Novaliq to reimagine topical dermatology.  Dermaliq’s mission is to develop a new generation of superior topical therapeutics and medical skin care products with greater efficacy and fewer unwanted side effects for millions of patients. The unique “hyliQTM” technology is driving a growing product pipeline in key dermatological indications. The technology offers superior bioavailability, stability and cosmetic acceptability. Dermaliq secured USD 15 million in a series A round to advance three transformative skin care drug therapies through clinical trials. Key shareholders are Novaliq GmbH, 3E Bioventures Capital and Beijing Whale Technology Corporation Ltd.